R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
In this study，lenalidomide was added in the first-line treatment in the newly diagnosed
highly invasively non-Hodgkin B-cell lymphoma. The R2-CHOP/R2-EPOCH etc was applied compared
with the classical R-CHOP/R-EPOCH etc. The investigators tried to explore a more effective
and safe treatment regimen for patients with high-risk B-cell lymphoma to improve the
patient's poor prognosis.